1887

Chapter 30 : Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch30-1.gif /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch30-2.gif

Abstract:

AIDS was first described in clinical terms in the United States in 1981, and in 1983, the cause was determined to be infection with a transmittable human retrovirus, eventually named human immunodeficiency virus type 1 (HIV-1). Globally, an estimated 35.3 (32.2 to 38.8) million people were living with HIV in 2012, with 2.3 (1.9 to 2.7) million new HIV infections globally, and 1.6 (1.4 to 1.9) million AIDS deaths in 2012 (http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf). This pandemic has highlighted the utility of laboratory diagnostics and its relevance to patient care and treatment monitoring. The concern for transmission via blood products motivated the development of an antibody test in 1985 (1). The current versions of these enzyme-linked immunoabsorbent assays detect IgG seroconversion within a median of 3 to 4 weeks after infection (2). Antiretroviral therapy (ART) came into use, starting with AZT monotherapy, in 1985, and eventually the available number and classes of drugs expanded, which led to a better understanding of viral dynamics. Currently, the standard for managing HIV-1 infected individuals is combination therapy with three or more drugs (http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0). During this phase of active drug development, viral load testing became the standard of care for managing response to therapy. With advances in therapy, long-term (years) suppression of viral load became possible, but selective drug pressure eventually led to drug resistance. The use of genotypic and occasionally phenotypic resistance testing to accurately direct changes in nucleotides that imply resistance to drug therapy is routine in HIV clinical practice. This chapter will focus on the available molecular tests for diagnosis, monitoring, and management of HIV-1 infected individuals.

Citation: Caliendo A, Kraft C. 2016. Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1, p 417-429. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch30
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Simplified HIV-1 genome with its nine genes and the long terminal repeat regions. The enzymes reverse transcriptase, protease, and integrase are all encoded within the gene.

Citation: Caliendo A, Kraft C. 2016. Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1, p 417-429. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch30
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819071.ch30
1. Johnson JE. 1987. Use of a commercial ELISA test for the diagnosis of infection by the AIDS virus, HIV, in a patient population. Diagn Microbiol Infect Dis 6:267271[CrossRef].[PubMed]
2. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. 2000. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 109:568576[CrossRef].[PubMed]
3. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436441[CrossRef].[PubMed]
4. Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, Hahn BH. 2001. The origins of acquired immune deficiency syndrome viruses: where and when? Philos Trans R Soc Lond B Biol Sci 356:867876[CrossRef].[PubMed]
5. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh C, Dia M, Gueye E, , et al. 1994. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:15871590[CrossRef].[PubMed]
6. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. 2008. The challenge of HIV-1 subtype diversity. N Engl J Med 358:15901602[CrossRef].[PubMed]
7. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F. 2009. A new human immunodeficiency virus derived from gorillas. Nat Med 15:871872[CrossRef].[PubMed]
8. Richman DD, Whitley RJ, Hayden FG. 2009. Clinical Virology, 3rd ed. ASM Press, Washington, DC.
9. Hunter E,. 2008. Retroviruses, p. 680. In Mahy BWJ, Van Regunmortel MH (ed.), Encyclopedia of Virology, 3rd ed. Elsevier, Atlanta, GA.
10. MacArthur RD, Novak RM. 2008. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47:236241[CrossRef].[PubMed]
11. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Muñoz A. 2007. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 297:23492350[CrossRef].[PubMed]
12. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:11671170[CrossRef].[PubMed]
13. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WJ, Kroner BL, Goedert JJ. 1996. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 276:105110[CrossRef].[PubMed]
14. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, Gupta P. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 122:573579[CrossRef].[PubMed]
15. Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM. 2001. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 135:954964[CrossRef].[PubMed]
16. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D. 1998. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12:16191624[CrossRef].[PubMed]
17. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK. 2001. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 286:171179[CrossRef].[PubMed]
18. Kahn JO, Walker BD. 1998. Acute human immunodeficiency virus type 1 infection. N Engl J Med 339:3339[CrossRef].[PubMed]
19. Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, Starr SE, Spector SA. 2002. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 185:14091416[CrossRef].[PubMed]
20. Zhuang J, Jetzt AE, Sun G, Yu H, Klarmann G, Ron Y, Preston BD, Dougherty JP. 2002. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol 76:1127311282[CrossRef].[PubMed]
21. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123126[CrossRef].[PubMed]
22. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:15821586[CrossRef].[PubMed]
23. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP. 2008. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22:385393[CrossRef].[PubMed]
24. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 5:e158[CrossRef].[PubMed]
25. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA III, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR, Team ACTGAS.AIDS Clinical Trials Group (ACTG) A5095 Study Team. 2010. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 201:662671.
26. Tang MW, Shafer RW. 2012. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72:e1e25[CrossRef].[PubMed]
27. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, Shaefer M. 2007. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials 8:18[CrossRef].[PubMed]
28. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14:F83F93[CrossRef].[PubMed]
29. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P. 2000. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther 5:6570.[PubMed]
30. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:21952199[CrossRef].[PubMed]
31. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM, VIRA3001 Study Team. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:579588[CrossRef].[PubMed]
32. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM, Narval Trial Group. 2002. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16:727736[CrossRef].[PubMed]
33. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD, California Collaborative Treatment Group. 2005. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 19:295302.[PubMed]
34. Dunn DT, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, McCormack S, Babiker AG, Darbyshire JH, Evaluation of Resistance Assays (ERA) Trial Investigators. 2005. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr 38:553559[CrossRef].[PubMed]
35. Pou C, Noguera-Julian M, Pérez-Álvarez S, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Gonzalez D, Sayada C, Chueca N, Pulido F, Ibáñez L, Rodríguez C, Casadellà M, Santos JR, Ruiz L, Clotet B, Paredes R. 2014. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. Clin Infect Dis 59:578588[CrossRef].[PubMed]
36. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. 2008. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46:16171623[CrossRef].[PubMed]
37. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51:566575[CrossRef].[PubMed]
38. Cartwright CP. 2006. The changing epidemiology of HIV/AIDS at a Minnesota hospital: impact of demographic change and viral diversity. J Med Virol 78(Suppl 1):S19S21[CrossRef].[PubMed]
39. Lin HH, Gaschen BK, Collie M, El-Fishaway M, Chen Z, Korber BT, Beatrice ST, Zhang L. 2006. Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr 41:399404[CrossRef].[PubMed]
40. Singer DE, Bautista CT, O'Connell RJ, Sanders-Buell E, Agan BK, Kijak GH, Hakre S, Sanchez JL, Sateren WB, McCutchan FE, Michael NL, Scott PT. 2010. HIV infection among U.S. Army and Air Force military personnel: sociodemographic and genotyping analysis. AIDS Res Hum Retroviruses 26:889894[CrossRef].[PubMed]
41. Gueudin M, Plantier JC, Damond F, Roques P, Mauclère P, Simon F. 2003. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. J Virol Methods 113:4349[CrossRef].[PubMed]
42. Swanson P, Holzmayer V, Huang S, Hay P, Adebiyi A, Rice P, Abravaya K, Thamm S, Devare SG, Hackett J Jr. 2006. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods 137:184192[CrossRef].[PubMed]
43. Karasi JC, Dziezuk F, Quennery L, Förster S, Reischl U, Colucci G, Schoener D, Seguin-Devaux C, Schmit JC. 2011. High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. J Clin Virol 52:181186[CrossRef].[PubMed]
44. Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Zidovec Lepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM, Tang Y-W, International Viral Load Assay Collaboration. 2014. Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol 52:517523[CrossRef].[PubMed]
45. Thomson MM, Nájera R. 2005. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 7:210224.[PubMed]
46. Styler SA, Myers AL, Donaldson DJ. 2013. Heterogeneous photooxidation of fluorotelomer alcohols: a new source of aerosol-phase perfluorinated carboxylic acids. Environ Sci Technol 47:63586367.[PubMed]
47. Jagodzinski LL, Liu Y, Hack HR, Kibirige C, Peel SA, Manak MM. 2014. Discrepant amplification results during the development of an assay leads to reclassification of two AIDS reagent repository HIV-2 isolates as HIV-1. PLoS One 9:e96554[CrossRef].[PubMed]
48. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, Danel C, Anglaret X, Leroy V, Msellati P, Dabis F, Rouzioux C. 2005. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 43:27092717[CrossRef].[PubMed]
49. Stewart P, Cachafeiro A, Napravnik S, Eron JJ, Frank I, van der Horst C, Bosch RJ, Bettendorf D, Bohlin P, Fiscus SA. 2010. Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. J Clin Virol 49:198204[CrossRef].[PubMed]
50. Ritchie AV, Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, Jendrulek I, McGuire M, Goel N, Sharma PI, Allain JP, Lee HH. 2014. SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings. J Clin Microbiol 52:33773383[CrossRef].[PubMed]
51. García-Bujalance S, Ladrón de Guevara C, González-García J, Arribas JR, Zamora F, Gutiérrez A. 2007. Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1. J Microbiol Methods 69:384386[CrossRef].[PubMed]
52. Griffith BP, Mayo DR. 2006. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT). J Clin Virol 35:197200[CrossRef].[PubMed]
53. Kraft CS, Binongo JN, Burd EM, Eaton ME, McCloskey CB, Fernandes H, Hill CE, Caliendo AM. 2013. Successful use of Plasma Preparation Tubes™ (PPTs) in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 test. J Clin Virol 57:7779[CrossRef].[PubMed]
54. Fernandes H, Morosyuk S, Abravaya K, Ramanathan M, Rainen L. 2010. Evaluation of effect of specimen-handling parameters for plasma preparation tubes on viral load measurements obtained by using the Abbott RealTime HIV-1 load assay. J Clin Microbiol 48:24642468[CrossRef].[PubMed]
55. Lofgren SM, Morrissey AB, Chevallier CC, Malabeja AI, Edmonds S, Amos B, Sifuna DJ, von Seidlein L, Schimana W, Stevens WS, Bartlett JA, Crump JA. 2009. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS 23:24592466[CrossRef].[PubMed]
56. Fiscus SA, Brambilla D, Grosso L, Schock J, Cronin M. 1998. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol 36:258260.[PubMed]
57. Lew J, Reichelderfer P, Fowler M, Bremer J, Carrol R, Cassol S, Chernoff D, Coombs R, Cronin M, Dickover R, Fiscus S, Herman S, Jackson B, Kornegay J, Kovacs A, McIntosh K, Meyer W, Michael N, Mofenson L, Moye J, Quinn T, Robb M, Vahey M, Weiser B, Yeghiazarian T. 1998. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. J Clin Microbiol 36:14711479.[PubMed]
58. Brambilla D, Jennings C, Aldrovandi G, Bremer J, Comeau AM, Cassol SA, Dickover R, Jackson JB, Pitt J, Sullivan JL, Butcher A, Grosso L, Reichelderfer P, Fiscus SA. 2003. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol 41:18881893[CrossRef].[PubMed]
59. Christo PP, Greco DB, Aleixo AW, Livramento JA. 2007. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis 7:147[CrossRef].[PubMed]
60. Nelson JA, Hawkins JT, Schanz M, Mollan K, Miller MB, Schmitz JL, Fiscus SA. 2014. Comparison of the Gen-Probe Aptima HIV-1 and Abbott HIV-1 qualitative assays with the Roche Amplicor HIV-1 DNA assay for early infant diagnosis using dried blood spots. J Clin Virol 60:418421[CrossRef].[PubMed]
61. Cassol S, Salas T, Gill MJ, Montpetit M, Rudnik J, Sy CT, O'Shaughnessy MV. 1992. Stability of dried blood spot specimens for detection of human immunodeficiency virus DNA by polymerase chain reaction. J Clin Microbiol 30:30393042.[PubMed]
62. Luo W, Yang H, Rathbun K, Pau CP, Ou CY. 2005. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol 43:18511857[CrossRef].[PubMed]
63. Piwowar-Manning E, Lugalia L, Kafufu B, Jackson JB. 2008. Comparison of results obtained with Amplicor HIV-1 DNA PCR test version 1.5 using 100 versus 500 microliters of whole blood. J Clin Microbiol 46:11041105[CrossRef].[PubMed]
64. Erali M, Page S, Reimer LG, Hillyard DR. 2001. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol 39:21572165[CrossRef].[PubMed]
65. Jagodzinski LL, Cooley JD, Weber M, Michael NL. 2003. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol 41:9981003[CrossRef].[PubMed]
66. Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, Bouchez O, Gabriel C, Izopet J, Kessler HH, Stelzl E, Di Giallonardo F, Schlapbach R, Radonic A, Paredes R, Recordon-Pinson P, Sakwa J, St John EP, Schmitz-Agheguian GG, Metzner KJ, Däumer MP, Group HIVA.454 HIV Alphastudy Group. 2014. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. J Virol Methods 204:3137.
67. Winters B, Van Craenenbroeck E, Van der Borght K, Lecocq P, Villacian J, Bacheler L. 2009. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods 162:101108[CrossRef].[PubMed]
68. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44:920928[CrossRef].[PubMed]
69. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, Ussery M, Kalish ML, Heneine W, García-Lerma JG. 2007. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45:517521[CrossRef].[PubMed]
70. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, García-Lerma JG. 2008. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 61:12171220[CrossRef].[PubMed]
71. Ziemniak C, Mengistu Y, Ruff A, Chen YH, Khaki L, Bedri A, Simen BB, Palumbo P, Eshleman SH, Persaud D. 2011. Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings. J Clin Microbiol 49:40774082[CrossRef].[PubMed]
72. MacArthur RD, Novak RM. 2008. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47:236241[CrossRef].[PubMed]
73. Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR. 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82:82108214[CrossRef].[PubMed]
74. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80:49094920[CrossRef].[PubMed]
75. McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2012. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr 61:279286[CrossRef].[PubMed]
76. Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quiñones-Mateu ME. 2012. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 7:e49602[CrossRef].[PubMed]
77. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. 1996. HIV viral load markers in clinical practice. Nat Med 2:625629[CrossRef].[PubMed]
78. Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, Herman S, Katzenstein D, Leung S, Lin HJ, Palumbo P, Rasheed S, Todd J, Vahey M, Reichelderfer P. 1996. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol 34:26952701.[PubMed]
79. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. 1996. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 174:401403[CrossRef].[PubMed]
80. O'Brien WA, Grovit-Ferbas K, Namazi A, Ovcak-Derzic S, Wang HJ, Park J, Yeramian C, Mao SH, Zack JA. 1995. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:10821089.[PubMed]
81. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB. 1995. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 182:17271737[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Current FDA-approved antiretroviral drugs

Citation: Caliendo A, Kraft C. 2016. Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1, p 417-429. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch30
Generic image for table
TABLE 2

FDA-approved molecular tests for quantification of HIV-1 RNA

Citation: Caliendo A, Kraft C. 2016. Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1, p 417-429. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch30
Generic image for table
TABLE 3

Selected assays for resistance testing

Citation: Caliendo A, Kraft C. 2016. Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1, p 417-429. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch30

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error